Advertisement

 

 

Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.

Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.
Author Information (click to view)

Mouton JP, Cohen K, Maartens G,


Mouton JP, Cohen K, Maartens G, (click to view)

Mouton JP, Cohen K, Maartens G,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert review of clinical pharmacology 2016 8 22() 1-11

Abstract
INTRODUCTION
WHO recommends tenofovir, efavirenz, and lamivudine or emtricitabine for first-line antiretroviral therapy (ART) in adults, which replaced more toxic regimens using stavudine, zidovudine or nevirapine.

AREAS COVERED
We searched Pubmed to identify observational studies and randomized controlled trials reporting toxicity of these antiretrovirals published between 2011 and 2016, and hand-searched abstracts presented at major HIV conferences in 2015 and 2016, focusing on data from sub-Saharan Africa. Tenofovir’s nephrotoxicity manifests as mild renal tubular dysfunction (common and of uncertain clinical significance), acute kidney injury (rare), and chronic declining glomerular filtration rate (common). African studies, which include high proportions of patients with renal dysfunction from opportunistic diseases, report population improvement in renal function after starting tenofovir-based ART. Tenofovir modestly decreases bone mineral density, and there is emerging data that this increases fracture risk. Efavirenz commonly causes early self-limiting neuropsychiatric toxicity and hypersensitivity rashes. Recent studies have highlighted its long-term neuropsychiatric effects, notably suicidality and neurocognitive impairment, and metabolic toxicities (dyslipidemia, dysglycemia, and lipoatrophy). We point out the challenges clinicians face in the recognition and attribution of adverse drug reactions. Expert commentary: Tenofovir and efavirenz are generally well tolerated, but both are associated with potentially serious toxicities. Pharmacovigilance systems in resource-limited settings with high HIV burden should be strengthened.

Submit a Comment

Your email address will not be published. Required fields are marked *

18 − 2 =

[ HIDE/SHOW ]